FindTrial
Sign In

Comparing 3 Schedules of Alimta Plus Gemzar

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00034606
Enrollment
Unknown
Registered
2002-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2006-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Keywords

Lung cancer, cancer, neoplasm, non-small, chemotherapy

Brief summary

The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.

Interventions

DRUGPemetrexed (Alimta) in combination with gemcitabine (Gemzar)

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of non-small lung cancer * No prior chemotherapy * Able to care for self

Exclusion criteria

* An ongoing infection * Pregnancy or breast feeding * Other serious medical condition * Cancer that has spread to the brain * Inability to take folic acid

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026